Corcept Therapeutics Inc's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Corcept Therapeutics Inc's ROA in the second quarter of 2026?
Corcept Therapeutics Inc achieved a return on average assets (ROA) of 6.55 % in its second quarter of 2026, this is above CORT's average return on assets of 3.45%.
Corcept Therapeutics Inc assets over the 12 months ending in its second quarter of 2026 are valued at $828 million

ROA has improved compared to 5.75% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 139 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2026 from 581 to 1069.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	8.44 %	-3.73 %	13.8 %	25.7 %	33.7 %
Y / Y Net Income Change	21.76 %	-	-21.36 %	-58.54 %	-1.45 %
Net Income (TTM) in million	54	47	98	105	132
Return On Assets (TTM)	6.55 %	5.75 %	11.98 %	13.17 %	17.54 %
CORT's Total Ranking	# 1069	# 581	# 459	# 312	# 307
Total Assets (TTM) in million	869	815	805	824	802
Seq. Total Assets Change	6.69 %	1.27 %	-2.3 %	2.73 %	-5.28 %
Seq. Net Income Change	-	-	23.52 %	-44.07 %	70.6 %

CORT's 5 Years Annual ROA >> Back to CORT Management Effectiveness >> Compare CORT ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 55
Sector	# 140
Overall	# 964

Return On Assets Statistics
High	Average	Low
104.75 %	3.45 %	-83.48 %
(Dec 31 2017)		(Jun 30 2012)

Financial Statements
Corcept Therapeutics Inc's Assets	$ 869 million	CORT's Balance sheet
Corcept Therapeutics Inc's Income	$ 42 million	Quarterly CORT's Income Statement
CORT's Income by Division		See CORT's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	40.98 %	32.92 %	1.75 %	31.78 %	-26.44 %
Total Assets in million	997	707	532	523	397
Y / Y Net Income Change	-29.74 %	32.45 %	4.15 %	-9.98 %	6.13 %
Net Income in million	98	140	105	101	113
Annual Return On Assets	9.85 %	19.76 %	19.83 %	19.37 %	28.36 %

CORT's 5 Years Annual ROA >> Back to CORT Management Effectiveness >> Compare CORT ROA to its Competitors

Comment on CORT's ROA in the fiscal year ending 2025

In the fiscal year 2025 Corcept Therapeutics Inc's ROA decreased compared to previous year to 9.85 %, due to deterioration of net income -29.74 % to $98.17 million, from $139.73 million a year ago, as CORT's assets were $996.92 million.

More Return On Assets Ratios
CORT's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CORT's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CORT's Competitors
Subscribers only: Roa for Corcept Therapeutics Inc's Suppliers
Subscribers only: Return On Assets for CORT's Customers

You may also want to know
CORT's Roi	CORT's Inventory Turnover Ratio	CORT's Growth Rates	CORT's Dividend Comparisons
	CORT's Profitability Ratios	CORT's Asset Turnover Ratio	CORT's Dividend Growth
CORT's Roe	CORT's Valuation Ratios	CORT's Financial Strength Ratios	CORT's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
United Therapeutics Corporation	17.98 %
Resmed Inc	17.80 %
Krystal Biotech Inc	17.65 %
Chemed Corporation	17.52 %
Zoetis Inc	17.19 %
Vertex Pharmaceuticals Inc	16.88 %
Halozyme Therapeutics Inc	16.55 %
Alnylam Pharmaceuticals Inc	15.76 %
Intuitive Surgical Inc	15.63 %
Healthcare Services Group Inc	15.21 %
Inspire Medical Systems inc	15.21 %
Dexcom Inc	14.87 %
Neurocrine Biosciences Inc	14.73 %
Entera Bio Ltd	14.60 %
Standard Biotools Inc	14.31 %
Arcutis Biotherapeutics Inc	14.23 %
Harmony Biosciences Holdings inc	14.15 %
Biolife Solutions Inc	14.09 %
Aveanna Healthcare Holdings Inc	13.82 %
West Pharmaceutical Services Inc	13.64 %
Medinotec Inc	13.38 %
Puma Biotechnology Inc	13.28 %
Sbc Medical Group Holdings Incorporated	13.26 %
Alpha Pro Tech Ltd	13.17 %
Illumina Inc	12.68 %
Spero Therapeutics Inc	12.57 %
Transmedics Group Inc	12.50 %
Eton Pharmaceuticals Inc	12.37 %
Nephros Inc	12.30 %
Msa Safety Inc	12.23 %

Date modified: 2026-08-13T08:10:46+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.